



### Publications

1. Voskoboynik M, Liu J, Song KH, Park DG, Ryu MH, Chon HJ, Kim C. A first-in-human phase 1 dose-escalation and expansion study of intratumoral oncolytic reovirus (RC402) as a monotherapy or in combination with pembrolizumab in advanced solid tumors. Poster presented at: *AACR Annual Meeting 2024*; April 5-10, 2024; San Diego, CA.
2. Lim Y, Park J, Lim JE, Park M, Koh SK, Lee M, Kim SK, Lee SH, Song KH, Park DG, Kim HY, Jeong BC, Cho D. Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy. *Scientific Reports*. 2024; 14:7390. <https://doi.org/10.1038/s41598-024-56297-7>
3. Woo JK, Kim T-G, Im NY, Son K-Y, Cho M, Jeong YJ, Hong J-I, Kang B, Enkhtaivan G, Cho N-H, et al. Dual-Armed Oncolytic Myxoma Virus Encoding IFN- $\gamma$  and CD47 Promotes Lymphocyte Infiltration and Tumor Suppression of Syngeneic Murine Melanoma. *Cancers*. 2023; 15(19):4703. <https://doi.org/10.3390/cancers15194703>
4. Song KH, Lee YR, Jeong YJ, Lee SH, Kim M, Lee HG, Cho NH, Park DG, Lee YS. Improved oncolytic reovirus RP116 has overcome resistance to immune checkpoint blockade therapy, as well as tumor recurrence and metastasis. Poster presented at: *49<sup>th</sup> Annual Meeting of Korean Cancer Association & 9<sup>th</sup> International Cancer Conference*; June 15-16, 2023; Seoul.
5. Park JS, Kim M. Reovirus safety study for proliferation and differentiation of human adipose-derived mesenchymal stem cells. *J Microbiol*. 2017;55(1):75-79. <https://doi.org/10.1007/s12275-017-6542-0>
6. Park JW, Kim M. Replicating viruses for gynecologic cancer therapy. *Eur J Gynaecol Oncol*. 2016;37(3):295-304. <https://pubmed.ncbi.nlm.nih.gov/27352554/>
7. Kim M. Naturally occurring reoviruses for human cancer therapy. *BMB Rep*. 2015;48(8):454-460. <https://doi.org/10.5483/BMBRep.2015.48.8.076>
8. Yoon JJ, Lee YT, Chu H, Son SY, Kim M. Phosphorylation of the nucleocapsid protein of Hantaan virus by casein kinase II. *J Microbiol*. 2015;53(5):343-347. <https://doi.org/10.1007/s12275-015-5095-3>
9. Kim M. Replicating poxviruses for human cancer therapy. *J Microbiol*. 2015;53(4):209-218. <https://doi.org/10.1007/s12275-015-5041-4>
10. Kim M, Rahman MM, Cogle CR, McFadden G. Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. *Biochem Biophys Res Commun*. 2015;462(4):283-287. <https://doi.org/10.1016/j.bbrc.2015.03.146>
11. Kim M. Reoviral Oncotropism Against c-Myc Overexpressing HS 68 Cells. *J Bacteriol Virol*. 2015;45(2):126-131. <http://doi.org/10.4167/jbv.2015.45.2.126>

12. Kaowinn S, Cho IR, Moon J, et al. Pancreatic adenocarcinoma upregulated factor (PAUF) confers resistance to pancreatic cancer cells against oncolytic parvovirus H-1 infection through IFNA receptor-mediated signaling. *Biochem Biophys Res Commun.* 2015;459(2):313-318. <https://doi.org/10.1016/j.bbrc.2015.02.107>
13. Madlambayan GJ, Bartee E, Kim M, et al. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. *Leuk Res.* 2012;36(5):619-624. <https://doi.org/10.1016/j.leukres.2012.01.020>
14. Kim M, Garant KA, zur Nieden NI, et al. Attenuated reovirus displays oncolysis with reduced host toxicity. *Br J Cancer.* 2011;104(2):290-299. <https://doi.org/10.1038/sj.bjc.6606053>
15. Kim M, Williamson CT, Prudhomme J, et al. The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. *Oncogene.* 2010;29(27):3990-3996. <https://doi.org/10.1038/onc.2010.137>
16. Kim M, Hansen KK, Davis L, et al. Z-FA-FMK as a novel potent inhibitor of reovirus pathogenesis and oncolysis in vivo. *Antivir Ther.* 2010;15(6):897-905. <https://doi.org/10.3851/imp1646>
17. Cho IR, Koh SS, Min HJ, et al. Reovirus infection induces apoptosis of TRAIL-resistant gastric cancer cells by down-regulation of Akt activation. *Int J Oncol.* 2010;36(4):1023-1030. [http://dx.doi.org/10.3892/ijo\\_00000583](http://dx.doi.org/10.3892/ijo_00000583)
18. Kim M, Madlambayan GJ, Rahman MM, et al. Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. *Leukemia.* 2009;23(12):2313-2317. <https://doi.org/10.1038%2Fleu.2009.219>
19. Rahman MM, Mohamed MR, Kim M, Smallwood S, McFadden G. Co-regulation of NF-kappaB and inflammasome-mediated inflammatory responses by myxoma virus pyrin domain-containing protein M013. *PLoS Pathog.* 2009;5(10):e1000635. <https://doi.org/10.1371%2Fjournal.ppat.1000635>
20. Kim M, Chung YH, Johnston RN. Reovirus and tumor oncolysis. *J Microbiol.* 2007;45(3):187-192. <https://pubmed.ncbi.nlm.nih.gov/17618222/>
21. Kim M, Egan C, Alain T, et al. Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. *Oncogene.* 2007;26(28):4124-4134. <https://doi.org/10.1038/sj.onc.1210189>
22. Alain T, Kim M, Johnston RN, et al. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. *Br J Cancer.* 2006;95(8):1020-1027. <https://doi.org/10.1038/sj.bjc.6603363>